| Objective: To investigate the clinical efficacy of long-acting GnRH agonist protocol,GnRH antagonist protocol and Progestin-primed ovarian stimulation protocol in controlled ovarian hyperstimulation in patients with polycystic ovary syndrome,and to find suitable methods for them 。 Methods:The clinical data of patients(263 cycles)who underwent IVF/ICSI-ET due PCOS or fallopian tube factor combined with PCOS in the Reproductive Medicine Center of the First Affiliated Hospital of Xinjiang Medical University from December 1,2018 to December 1,2021 were retrospectively analyzed.According to the different ovulation induction protocols,the patients were divided into three groups:140cases with long-acting GnRH agonist long protocol(group A),79 cases in GnRH antagonist protocol(group B);and 44 cases in Progestin-primed ovarian stimulation protocol(group C).The basic information,laboratory indicators and pregnancy outcomeof the three groups were compared.Results:There were no statistical significance in the general conditions(P>0.05).The gonadotropin(Gn)days and the total Gn doses、LH on h CG day、E2 on h CG day in the three groups have statistically significant(P<0.05).There were no significant differences in the number of retrieved oocytes,the number of high quality embryos,the number of available embryos,cycle cancellation rate due to no available embryos,the clinical pregnancy rate and the abortion rate among the groups(P> 0.05).Significant differences of incidence of moderate to severe ovarian hyperstimulation syndrome(OHSS)and fresh embryo transfer rate was found between the three groups(P<0.05).Conclusion:1.For PCOS patients at relatively low risk of OHSS,long protocol and fresh embryo transfer can be selected.2.Compared with other protocols,the GnRH antagonist protocol can shorten the number of Gn days,reduce the amount of Gn,and lower the incidence of OHSS,so it is the preferred controlled ovarian hyperstimulation for PCOS patients.3.Pregnancy outcomes of PPOS were similar to those of other protocols,PPOS can be used as one of the options for COH in PCOS patients. |